Skip to main content

Developing Multispecific Biological Agents that Target Tumor Neovasculature for Cancer Imaging and Therapy

Objective

The dysregulation of signaling pathways that mediate cell proliferation, survival and migration is an underlying cause of many cancers. In particular, dysregulation and over-expression of avb3 integrin, membrane-type-1 matrix metalloproteinase (MT1-MMP; also known as matrix metalloproteinase-14, MMP14) and vascular endothelial growth factor receptor-2 (VEGFR2) correlate with poor prognosis in many human tumors, making these proteins attractive targets for therapeutic intervention. Numerous papers have demonstrated the cross-talk between biological processes mediated by αvβ3 integrins, MT1-MMP, VEGFR2, and their ligands, particularly pathways responsible for angiogenesis. Dual-specific proteins that can target and inhibit the activity of the above multiple receptors therefore have superior potential to single-targeted agents due to differential expression of these disease markers in different patients and the ability of this expression to change over time. Most currently available bispecific protein therapeutics comprise antibodies (Abs) or antibody fragments. The new approach proposed here entails rational and combinatorial methods for engineering multispecificity into small peptides and natural protein ligands to function as non-immunoglobulin alternatives to antibodies. In this innovative approach to creating dual-specific proteins, an additional functionality is introduced into a small peptide or into a natural protein ligand to complement its existing biological properties. We predict that this approach will form a major part of a highly effective strategy for creating ligand-based multispecific receptor inhibitors and molecular tools for protein recognition. We envision that protein variants generated from these efforts will promote the next generation of therapeutics including, but not limited to, molecular imaging agents, targeted drug delivery agents, and selective tissue targeting probes.

Field of science

  • /social sciences/sociology/social problems/migration
  • /natural sciences/biological sciences/biochemistry/biomolecules/proteins
  • /medical and health sciences/clinical medicine/oncology/cancer

Call for proposal

ERC-2013-StG
See other projects for this call

Funding Scheme

ERC-SG - ERC Starting Grant

Host institution

BEN-GURION UNIVERSITY OF THE NEGEV
Address
.
84105 Beer Sheva
Israel
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 625 000
Principal investigator
Niv Papo (Dr.)
Administrative Contact
Daphna Tripto (Ms.)

Beneficiaries (1)

BEN-GURION UNIVERSITY OF THE NEGEV
Israel
EU contribution
€ 1 625 000
Address
.
84105 Beer Sheva
Activity type
Higher or Secondary Education Establishments
Principal investigator
Niv Papo (Dr.)
Administrative Contact
Daphna Tripto (Ms.)